We are very grateful to have contributed and to face a new crowdinvesting record with the #PROFEM Going Public Convertible Loan. € 4800 per capita investment volume is a record for an Austrian Start-Up. Of course after 14 successful years of developing the drug Candiplus©, #PROFEM is only economically a Start-Up at the moment. The founders #MarionNoe and #ChristianNoe plan double digit profits within the next years. Licensing agreements and a broad platform of further drug candidates are the economic basis for a planned IPO in 2028. „More to come“ means to enable #PROFEM a global market leading position in the gynecology market, a niche sector within the pharma industry. Women’s health, especially in the underdeveloped gynecology sector is far more than a commercial target, it is an important impact mission. By starting exploratory talks with strategic investors in the women’s health sector and by generating further growth capital, we look forward realising the next milestones. 🚀 💯 🚀
Special thanks to the „lead testimonial“ #AlbertSchmidbauer for his commitment and the sponsoring of #BIOGENA crowd-campaign goodies.
All the best for the #PROFEM Management, #MarionNoe and #KarinVilsmeier for the upcoming final EMA steps and US Market entrance.
#PROFEM #Crowdinvesting #GoingPublicConvertibleLoan #Women’sHealth #C4Holding
Vienna, February 2nd 2026
